Matthew Moyer is a Gastroenterology physician affiliated with Penn State Milton S. Hershey Medical Center. OpenAlex indexes 188 publications with 1,312 citations (h-index 20); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingClinical trials
- CHARM II: Chemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts
Sponsor: Milton S. Hershey Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
54.5%Solutions for parenteral nutrition54.5%Peg 3350-Electrolyte100%Part D≥24 patientsMetabolism & gastrointestinal
45.5%Proton pump inhibitor45.5%Omeprazole100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2018–2022 per NIH RePORTER. The latest:
- CHARM 2: Chemotherapy for ablation and resolution of mucinous pancreatic cysts: a prospective, randomized, double-blind, multi-center clinical trial
Pennsylvania State Univ Hershey Med Ctr
FY2022$409,653R01CA222648 - CHARM 2: Chemotherapy for ablation and resolution of mucinous pancreatic cysts: a prospective, randomized, double-blind, multi-center clinical trial
Pennsylvania State Univ Hershey Med Ctr
FY2021$413,177R01CA222648 - CHARM 2: Chemotherapy for ablation and resolution of mucinous pancreatic cysts: a prospective, randomized, double-blind, multi-center clinical trial
Pennsylvania State Univ Hershey Med Ctr
FY2020$431,536R01CA222648
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Nancy Olsen, MD
Penn State Milton S. Hershey Medical Center
Joel Sorosky, MD
Penn State Milton S. Hershey Medical Center
Shin Mineishi, MD
Penn State Milton S. Hershey Medical Center
Catharine Paules, MD
Penn State Milton S. Hershey Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”